@BPharmCatalyst BioPharmCatalyst

BioPharmCatalyst posts on X about watch, strong, $aldx, $btai the most. They currently have [------] followers and [---] posts still getting attention that total [-----] engagements in the last [--] hours.

Engagements: [-----] #

[--] Week [------] +6.60%
[--] Month [------] +76%
[--] Months [-------] -73%
[--] Year [---------] -51%

Mentions: [--] #

[--] Week [--] +30%
[--] Month [--] +66%
[--] Months [---] -4.80%
[--] Year [---] +3.90%

Followers: [------] #

[--] Week [------] +0.03%
[--] Month [------] +0.25%
[--] Months [------] +2.40%
[--] Year [------] +5%

CreatorRank: [---------] #

Social Influence

Social category influence stocks 67.16% cryptocurrencies 19.4% finance 15.67% technology brands 2.24% currencies 2.24% exchanges 0.75% countries 0.75%

Social topic influence watch 9.7%, strong 7.46%, $aldx 6.72%, $btai 5.97%, $srpt 5.22%, $qncx #20, $imgn 5.22%, $fbio 5.22%, list 5.22%, $axsm 4.48%

Top accounts mentioned or mentioned by @mwb741 @sheffstation @fthealth @microcaptrader @yusufhameed @auditor112017 @markmarkuu @grok

Top assets mentioned Sarepta Therapeutics, Inc. (SRPT) Immunogen Inc (IMGN) Axsome Therapeutics, Inc (AXSM) Biomea Fusion, Inc. (BMEA) PTC Therapeutics, Inc. (PTCT) Journey Medical Corporation (DERM) Travere Therapeutics, Inc. Common Stock (TVTX) Merck & Co., Inc. (MRK) Pharming Group N.V. (PHAR) AbbVie Inc (ABBV) Pfizer, Inc. (PFE) Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Eli Lilly and Company (LLY) Amicus Therapeutics, Inc (FOLD) Vertex Protocol (VRTX) Cytokinetics Inc. (CYTK) Cidara Therapeutics, Inc. (CDTX) Taysha Gene Therapies, Inc. (TSHA) Amgen, Inc. (AMGN) Immuneering Corporation (IMRX) LYRA (LYRA) Rallybio Corporation (RLYB) Alzamend Neuro, Inc. (ALZN) Arrowhead Research Corporation (ARWR) Acadia Pharmaceuticals Inc. (ACAD) Halozyme Therapeutics, Inc. (HALO) Regeneron Pharmaceuticals Inc (REGN) GSK plc (GSK) Axon Enterprise, Inc. (AXON) ArriVent BioPharma, Inc. (AVBP) Contineum Therapeutics, Inc (CTNM) Sagimet Biosciences Inc. (SGMT) Atea Pharmaceuticals, Inc. (AVIR) Adlai Nortye Ltd (ANL) Align Technology, Inc. (ALGN) Evommune, Inc. (EVMN) Elevai Labs, Inc. (ELAB) Arcutis Biotherapeutics, Inc. (ARQT) SpringWorks Therapeutics, Inc. Common Stock (SWTX) AltLayer (ALT) Novartis AG (NVS)

Top Social Posts

Top posts by engagements in the last [--] hours

"$IRON received a CRL from the FDA for bitopertin in erythropoietic protoporphyria (EPP) with the agency acknowledging that the Phase [--] AURORA and BEACON trials showed significant reductions in whole blood metal-free PPIX and strong mechanistic support for the biomarker but concluding the data did not demonstrate a clear association between PPIX reductions and sunlight exposure-based clinical endpoints. The FDA indicated that results from the ongoing Phase [--] APOLLO trial could support traditional approval with topline data expected in Q4 [----]. The company plans to request a Type A meeting with"
X Link 2026-02-13T20:24Z 30.7K followers, [----] engagements

"$CLSD filed for Chapter [--] bankruptcy and will pursue a sale of its assets under Section [---] aiming to maximize stakeholder value via its SCS Microinjector platform five licensing deals with royalty potential and clinical-stage programs including Phase 3-ready CLS-AX for wet AMD and IND-ready assets in geographic atrophy and DME. $CLSD $ENLV $PMN $INSP $NVO $GNTA $ADTX $NAOV $SHPH $OABI See More Pre-market Movers https://www.biopharmcatalyst.com/news/2025/clearside-biomedical-clsd-chapter-11-enlivex-therapeutics-enlv-phase-2a-data-pipe"
X Link 2025-11-24T13:40Z 30.7K followers, [----] engagements

"$HURA entered a definitive agreement to raise https://www.biopharmcatalyst.com/news/2025/wave-life-wve-phase-1-data-structure-therapeutics-gpcr-phase-2-weight-loss-data https://www.biopharmcatalyst.com/news/2025/wave-life-wve-phase-1-data-structure-therapeutics-gpcr-phase-2-weight-loss-data"
X Link 2025-12-09T21:30Z 30.7K followers, [----] engagements

"$IMRX announced encouraging updated Phase 2a data for Atebimetinib in combination with modified gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer showing a 64% 12-month overall survival rate vs. https://www.biopharmcatalyst.com/news/2026/immuneering-imrx-phase-2a-data-eli-lilly-lly-will-acquire-ventyx-biosciences-vtyx https://www.biopharmcatalyst.com/news/2026/immuneering-imrx-phase-2a-data-eli-lilly-lly-will-acquire-ventyx-biosciences-vtyx"
X Link 2026-01-08T13:40Z 30.7K followers, [----] engagements

"$CGON announced that topline Phase [--] data from the PIVOT-006 trial evaluating cretostimogene as adjuvant monotherapy in intermediate-risk NMIBC is now expected in 1H [----] nearly a year ahead of schedule due to rapid enrollment. As the first randomized registrational trial in this underserved patient group the study's accelerated timeline highlights strong clinical interest and significant unmet need potentially positioning cretostimogene as the first FDA-approved option for this indication. $AQST $CGON $QURE $IBIO $KALV $LQDA $ZVSA $ELVN $GRI $WINT See More Biotech Updates👇"
X Link 2026-01-09T21:30Z 30.7K followers, [----] engagements

"$LYRA has suspended development of LYR-210 for chronic rhinosinusitis and is implementing a full workforce reduction retaining only key executives as consultants while pursuing strategic alternatives with SSG Capital Advisors. The move effectively ends active operations as the company shifts focus to preserving capital and exploring options for its lead asset. $LYRA $DAWN $ABVX $BDSX $TEM $ADPT $JAGX $IRIX $MESO $WOK See More Pre-market Movers https://www.biopharmcatalyst.com/news/2026/lyra-therapeutics-lyra-suspended-lyr-210-development-day-one-dawn-revenue-update"
X Link 2026-01-12T13:40Z 30.7K followers, [----] engagements

"$ATRA received an FDA Complete Response Letter for EBVALLO reversing prior alignment by now deeming the single-arm ALLELE trial insufficient to support accelerated approval for EBV+ PTLD. $ATRA $LYRA $BIOA $DAWN $BDSX $FHTX $CLRB $FBRX $WINT $SHPH See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2026/atara-atra-57-crl-lyra-lyra-45-lyr-210-suspended https://www.biopharmcatalyst.com/news/2026/atara-atra-57-crl-lyra-lyra-45-lyr-210-suspended"
X Link 2026-01-12T21:30Z 30.7K followers, [----] engagements

"BioPharmCatalyst Weekly #Watchlist BioPharmCatalyst Weekly Watchlist: Key PDUFA and Regulatory Catalysts for the next [--] months $AXSM $RGNX $REPL $RCKT $RYTM $ARVN $TVTX $MNKD $DNLI $ACHV https://www.biopharmcatalyst.com/news/2026/biopharmcatalyst-weekly-watchlist-key-pdufa-and-regulatory-catalysts-for-the-next-6-months-2 https://www.biopharmcatalyst.com/news/2026/biopharmcatalyst-weekly-watchlist-key-pdufa-and-regulatory-catalysts-for-the-next-6-months-2"
X Link 2026-01-16T21:28Z 30.7K followers, [----] engagements

"$MOVE reported that its merger partner Corvex secured a long-term lease for Nvidia H200 GPUs. The companies announced an all-stock merger in November with Corvex shareholders to own https://www.biopharmcatalyst.com/news/2026/greenwich-lifesciences-glsi-manufacturing-update-gri-bio-gri-reverse-stock-split https://www.biopharmcatalyst.com/news/2026/greenwich-lifesciences-glsi-manufacturing-update-gri-bio-gri-reverse-stock-split"
X Link 2026-01-23T13:40Z 30.7K followers, [----] engagements

"BioPharmCatalyst Weekly #Watchlist BioPharmCatalyst Weekly Watchlist: Key mid-2026 and Other Near-term Catalysts $NTLA $RLYB $MNOV $SDGR $OCS $BMEA $SGMT $AVBP $AVIR $CTNM https://www.biopharmcatalyst.com/news/2026/biopharmcatalyst-weekly-watchlist-key-mid-2026-and-other-near-term-catalysts https://www.biopharmcatalyst.com/news/2026/biopharmcatalyst-weekly-watchlist-key-mid-2026-and-other-near-term-catalysts"
X Link 2026-01-23T21:20Z 30.7K followers, [----] engagements

"$ADAG ended [----] with $74.5M in cash funding operations into late [----]. A Q1 [----] data update is expected from the Phase 1b/2 study of muzastotug + pembrolizumab in 3L+ MSS colorectal cancer. In [----] muzastotug received FDA Fast Track designation and showed promising early efficacy/safety. $MOVE $ADAG $REVB $PRFX $CHRS $BHC $ANL $SCNI $IOBT $BNR See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2026/adagene-adag-23-update-movano-move-140-nvidia-deal https://www.biopharmcatalyst.com/news/2026/adagene-adag-23-update-movano-move-140-nvidia-deal"
X Link 2026-01-23T21:34Z 30.7K followers, [----] engagements

"$MRK has ended acquisition talks with $RVMD after failing to agree on a valuation with discussions reportedly valuing the biotech at around $30 billion. $SXTP $RVMD $REVB $SRPT $IOBT $COGT $ABOS $INMD $TBPH $MESO See More Pre-market Movers https://www.biopharmcatalyst.com/news/2026/revolution-medicines-rvmd-acquistion-talks-with-mrk-end-60-degrees-pharmaceuticals-sxtp-delisting https://www.biopharmcatalyst.com/news/2026/revolution-medicines-rvmd-acquistion-talks-with-mrk-end-60-degrees-pharmaceuticals-sxtp-delisting"
X Link 2026-01-26T13:40Z 30.7K followers, [----] engagements

"BioPharmCatalyst Weekly Watchlist: Key mid-2026 and Other Near-Term Catalysts $NTLA $RLYB $MNOV $SDGR $OCS $BMEA $SGMT $AVBP $AVIR $CTNM https://www.biopharmcatalyst.com/news/2026/biopharmcatalyst-weekly-watchlist-key-mid-2026-and-other-near-term-catalysts https://www.biopharmcatalyst.com/news/2026/biopharmcatalyst-weekly-watchlist-key-mid-2026-and-other-near-term-catalysts"
X Link 2026-01-29T16:29Z 30.7K followers, [----] engagements

"$ANL was initiated with a Buy rating and $11 price target by Lucid Capital citing its pan-RAS inhibitor AN9025 as a key potential value driver as the asset becomes de-risked $VIVS $ANL $CORT $APRE $PMN $LXRX $ANEB $APM $QNCX $DRMA See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2026/vivosim-labs-vivs-commercial-access-china-sxt-pharmaceuticals-sxtc-reverse-split https://www.biopharmcatalyst.com/news/2026/vivosim-labs-vivs-commercial-access-china-sxt-pharmaceuticals-sxtc-reverse-split"
X Link 2026-01-30T22:05Z 30.7K followers, [----] engagements

"BioPharmCatalyst Weekly #Watchlist BioPharmCatalyst Weekly Watchlist: Key Catalysts Over The Next Two months $GOSS $RGNX $PVLA $KOD $ALDX $ACET $TBPH $FGEN $KPTI $ALZN https://www.biopharmcatalyst.com/news/2026/biopharmcatalyst-weekly-watchlist-key-catalysts-over-the-next-two-months https://www.biopharmcatalyst.com/news/2026/biopharmcatalyst-weekly-watchlist-key-catalysts-over-the-next-two-months"
X Link 2026-01-31T16:00Z 30.7K followers, [----] engagements

"$PHAR announced that the FDA issued a Complete Response Letter for the sNDA to expand Joenja (leniolisib) for APDS patients aged [---] citing concerns about potential underexposure in lower-weight children and an analytical testing method. $AQST $CATX $PHAR $SER $HIND $SGMT $SXTC $APLM $BCAB $ATOS See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2026/aquestive-therapeutics-crl-perspective-therapeutics-catx-offering https://www.biopharmcatalyst.com/news/2026/aquestive-therapeutics-crl-perspective-therapeutics-catx-offering"
X Link 2026-02-02T21:34Z 30.7K followers, [----] engagements

"$ALGN topped Wall Street estimates for both earnings and revenue. Driven by strong demand for its Invisalign system Align reported Q4 adjusted earnings of $3.29 per share on revenue of $1.05 billionabove analyst expectations of $2.97 per share and $1.03 billion. Clear Aligner revenue grew 5.5% to $838 million. For Q1 Align guided revenue between $1.01 billion and $1.03 billion and projected a 19.5% operating margin slightly below consensus. While Needhams David Saxon maintained a Hold rating he noted the outlook was fairly achievable amid strong U.S. and international sales. $ALGN $ALXO $TPST"
X Link 2026-02-05T13:40Z 30.7K followers, [----] engagements

"$NVST reported strong Q4 [----] results with core sales growth of 10.8% and a 22% increase in adjusted EBITDA to $111 million. Adjusted EPS rose 58% year-over-year to $0.38. For full-year [----] core sales grew 6.5% and adjusted EBITDA increased 26% reaching $372 million. CEO Paul Keel highlighted solid growth across all major businesses and geographies improved employee engagement and $166 million returned to shareholders via stock buybacks. Envista guided for [----] adjusted EPS of $1.35$1.45 core sales growth of 24% and free cash conversion of"
X Link 2026-02-06T13:40Z 30.7K followers, [----] engagements

"BioPharmCatalyst Weekly #Watchlist BioPharmCatalyst Weekly Watchlist: Anticipated Key Catalysts Due Over Next [--] Months $AXSM $DNLI $MIRM $NBTX $RYTM $ADCT $VRDN $OCS $AVIRI $CTMN https://www.biopharmcatalyst.com/news/2026/biopharmcatalyst-weekly-watchlist-anticipated-key-catalysts-due-over-next-6-months-2 https://www.biopharmcatalyst.com/news/2026/biopharmcatalyst-weekly-watchlist-anticipated-key-catalysts-due-over-next-6-months-2"
X Link 2026-02-06T21:45Z 30.7K followers, [----] engagements

"$TNON reaffirmed its strong [----] revenue outlook projecting Q4 revenue of $1.45M$1.48M (up https://www.biopharmcatalyst.com/news/2026/tenon-medical-tnon-earnings-guidance-artelo-biosciences-artl-equity-purchase-agreement https://www.biopharmcatalyst.com/news/2026/tenon-medical-tnon-earnings-guidance-artelo-biosciences-artl-equity-purchase-agreement"
X Link 2026-02-09T13:40Z 30.7K followers, [----] engagements

"$RGNX announced the FDA has issued a Complete Response Letter (CRL) for its BLA submission of RGX-121 for MPS II (Hunter syndrome) citing concerns over patient eligibility criteria use of external controls and surrogate endpoints. $RGNX $TNON $HUMA $LNAI $BCAB $QNCX $ENSC $HURA $ERNA $LYRA See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2026/regenxbio-rgnx-halt-complete-response-letter-crl-humacyte-huma-30-dod-funding https://www.biopharmcatalyst.com/news/2026/regenxbio-rgnx-halt-complete-response-letter-crl-humacyte-huma-30-dod-funding"
X Link 2026-02-09T21:39Z 30.7K followers, [----] engagements

"$QNCX announced that it is hiring LifeSci Capital to explore strategic alternatives including partnerships M&A licensing or balance-sheet restructuring though no outcome or timeline has been disclosed. $QNCX $EVMN $NKTR $PHIO $BRTX $PHGE $HURA $LNAI $ENSC $TECX See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2026/quince-qncx-306-strategic-alternatives-nektar-nktr-51-phase-2b-data https://www.biopharmcatalyst.com/news/2026/quince-qncx-306-strategic-alternatives-nektar-nktr-51-phase-2b-data"
X Link 2026-02-10T21:31Z 30.7K followers, [----] engagements

"$ONCY reported significant coordinated insider buying across all executive and board levels on February [----] [----]. Purchases between $0.83 and $0.86 per share signal strong confidence at the current price; shares closed up 26%. $IRON $ONCY $PHIO $CHRS $OKYO $EVMN $AIM $ICLR $INTS $UPB See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2026/disc-iron-22-complete-response-letter-crl-oncolytics-oncy-27-insider-buys https://www.biopharmcatalyst.com/news/2026/disc-iron-22-complete-response-letter-crl-oncolytics-oncy-27-insider-buys"
X Link 2026-02-13T21:35Z 30.7K followers, [----] engagements

"$SGMO priced a $25M+ offering amid strong Phase 1/2 STAAR data showing ST-920 improved kidney and cardiac function in Fabry disease supporting a rolling BLA submission to FDA. $SGMO $ELAB $RLYB $ERNA $EVO $RLAY $CDT $EPRX $SXTC $QNCX See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2026/sangamo-therapeutics-sgmo-31-private-placement-pmgc-holdings-elab-40-acquisition https://www.biopharmcatalyst.com/news/2026/sangamo-therapeutics-sgmo-31-private-placement-pmgc-holdings-elab-40-acquisition"
X Link 2026-02-03T21:40Z 30.7K followers, [----] engagements

"10 Biotech Catalysts final wk June $ALDR $CARA $PBYI $ACHN $CYTR $GEMP $MTNB $NEOT $PTI $RARX +Biotech Wk in Review https://www.biopharmcatalyst.com/news/2017/ten-biotech-catalysts-for-the-last-week-of-june-biotech-week-in-review-23-june-2017 https://www.biopharmcatalyst.com/news/2017/ten-biotech-catalysts-for-the-last-week-of-june-biotech-week-in-review-23-june-2017"
X Link 2017-06-24T13:00Z 30.7K followers, [--] engagements

"Next week details of BioPharmCatalyst Premium will be unveiled. What you see now will continue to be freely available with premium users getting access to an enhanced FDA Calendar and other tools. Look forward to showing you more next week"
X Link 2018-03-29T16:39Z 30.7K followers, [--] engagements

"Happy Thanksgiving to all - thank you for your feedback and use of BioPharmCatalyst. Next daily update will be on Monday (markets closed Thur early close Fri 1pm)"
X Link 2019-11-27T23:03Z 30.7K followers, [--] engagements

"Biotech updates 06/22/20: $MYOV Ph3 data Tue PM $KPTI FDA Approval $FPRX upgrade +45% $EVOK +62% $CLSN offering -20% Pipeline updates $ABBV $ARQT $AUPH $BNTX $CRBP $EVLO $ONTX $PFE $SWTX $ZIOP https://www.biopharmcatalyst.com/news/2020/myovant-myov-phase-3-data-to-be-released-pre-market-tuesday-karyopharm-kpti-fda-approval https://www.biopharmcatalyst.com/news/2020/myovant-myov-phase-3-data-to-be-released-pre-market-tuesday-karyopharm-kpti-fda-approval"
X Link 2020-06-23T00:50Z 30.7K followers, [--] engagements

"Biotech updates 06/29/20 $AKRO data Tue AH $ICPT CRL -40% $HRTX CRL -28% - $PCRX +18% $KNSA data +13% $VRCA CMC issues -19% $OBSV data Jul [--] Offerings $ACHV $CRSP $LQDA $XLRN Pvte placemts $BNTX $TRPX Pipe updates $ALT $ITRM $MRK $NMTR $SGEN $TFFP $TNXP https://www.biopharmcatalyst.com/news/2020/intercept-icpt-40-and-heron-hrtx-28-issued-complete-response-letters-akero-akro-data-due-tuesday https://www.biopharmcatalyst.com/news/2020/intercept-icpt-40-and-heron-hrtx-28-issued-complete-response-letters-akero-akro-data-due-tuesday"
X Link 2020-06-29T22:51Z 30.7K followers, [--] engagements

"Biotech updates 07/21/20: $MESO AdCom August [--] $AUPH PDUFA (p/r) Jan [--] $CASI offering -10% AH $MGEN analyst coverage +9% $ALEC open label presntn Jul [--] $IMRN +42% Pipeline updates $ABBV $ALEC $ARCT $BHVN $CERC $CYDY $IFRX $IRWD $NMTR $NVS $PSTI https://www.biopharmcatalyst.com/news/2020/mesoblast-meso-advisory-committee-meeting-set-for-august-13 https://www.biopharmcatalyst.com/news/2020/mesoblast-meso-advisory-committee-meeting-set-for-august-13"
X Link 2020-07-21T22:35Z 30.7K followers, [--] engagements

"BioPharmCatalyst updates 02/01/21 $VIE acquired +52% $ARQT +ve data +30% $DVAX #CovidVaccine update +63% $APLT hold lifted +21% $ADMS FDA approval+15% $MTNB miss -34% $CNCE fail -28% $NVAX +21% momo+coverage $PRTA +29% AH Offerings $ARGX $ARQT $EYPT $RVMD https://www.biopharmcatalyst.com/news/2021/viela-vie-acquired-by-horizon-hznp-52-arcutis-arqt-rallies-on-positive-late-stage-data-30 https://www.biopharmcatalyst.com/news/2021/viela-vie-acquired-by-horizon-hznp-52-arcutis-arqt-rallies-on-positive-late-stage-data-30"
X Link 2021-02-01T23:54Z 30.7K followers, [--] engagements

"BioPharmCatalyst updates 02/12/21 $GTHX FDA approval $PRTA upgrade +46% $MNKKQ PDUFA deferred #COVID19 $SESN update Feb [--] $LLY Tanezumab Adcom Mar [--] Offerings $CLBS $HEPA $PHIO $IMGN +30%; $FOLD -33% Pipeline updates $IMGN $KTRA $MACK $MDNA $OCUL $PFE https://www.biopharmcatalyst.com/news/2021/g1-therapeutics-gthx-fda-approval-prothena-prta-analyst-upgrade-46 https://www.biopharmcatalyst.com/news/2021/g1-therapeutics-gthx-fda-approval-prothena-prta-analyst-upgrade-46"
X Link 2021-02-12T22:50Z 30.7K followers, [--] engagements

"BioPharmCatalyst Updates 10/11/21: $OCUL Approval +15% $PTGX Hold removed +94% $SUPN Acquisition $ADMS +75% $PCRX Acquisition $FLXN +59% $PROG +59%; $TRVI +25% $IMRX -19%; $VYGR -14% Pipeline Updates: $MRK $LABP $PLX $AZN $ATNX $SRPT $AMTI $TPTX https://www.biopharmcatalyst.com/news/2021/ocular-ocul-15-approval-protagonist-ptgx-94-clinical-hold-removed https://www.biopharmcatalyst.com/news/2021/ocular-ocul-15-approval-protagonist-ptgx-94-clinical-hold-removed"
X Link 2021-10-11T21:48Z 30.7K followers, [--] engagements

"$PHRRF announced that the FDA has approved the Company's ketamine product herein referred to as KETARx on August 8th [----] for its indicated uses in surgical pain management. https://www.biopharmcatalyst.com/company/PHRRF/news/287382 https://www.biopharmcatalyst.com/company/PHRRF/news/287382"
X Link 2025-08-11T13:30Z 30.7K followers, [----] engagements

"$NWBO will acquire contract manufacturer Advent BioServices aiming to fully integrate operations gain manufacturing assets and IP cancel 19M previously issued securities and position for operational scale-up with expected cost and efficiency synergies. $BTAI $ELMD $AZTR $VIR $MAIA $RENB See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2025/azitra-aztr-dosed-first-patient-bioxcel-btai-phase-3-data https://www.biopharmcatalyst.com/news/2025/azitra-aztr-dosed-first-patient-bioxcel-btai-phase-3-data"
X Link 2025-08-27T20:30Z 30.7K followers, [----] engagements

"$GHRS announced that the FDA has lifted the clinical hold on its Investigational New Drug Application (IND) for GH001. Phase [--] is planned for [----]. $GHRS $RDHL $ALT $ZBIO $SLRX $NMRA $CNTX $TENX $PLRZ $GOVX See More Pre-market Movers https://www.biopharmcatalyst.com/news/2026/gh-research-ghrs-hold-lifted-altimmune-alt-breakthrough-therapy-designation https://www.biopharmcatalyst.com/news/2026/gh-research-ghrs-hold-lifted-altimmune-alt-breakthrough-therapy-designation"
X Link 2026-01-05T13:40Z 30.7K followers, [----] engagements

"$TIL announced that its subsidiary Axion Bio has discontinued development of AXN-2510 and terminated its license agreement with ImmuneOnco returning all rights to ImmuneOnco while retaining a limited license solely to wind down clinical activities. $TIL $ALMS $CYCN $DRUG $RNAZ $KALA $WVE $ARWR $RDHL $INM See More Pre-market Movers https://www.biopharmcatalyst.com/news/2026/instil-til-terminated-license-agreement-alumis-alms-phase-3-data http://1541.HK https://www.biopharmcatalyst.com/news/2026/instil-til-terminated-license-agreement-alumis-alms-phase-3-data http://1541.HK"
X Link 2026-01-06T13:40Z 30.7K followers, [----] engagements

"$VTYX surged after hours on reports that $LLY is in advanced talks to acquire the company with a deal potentially imminent. Ventyx focused on oral therapies for inflammatory diseases currently has a $600M market cap. $VTYX $ALMS $CYCN $TIL $ACRV $DRUG $RGC $BIOA $MREO $BNR See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2026/alumis-alms-phase-3-data-cyclerion-cycn-collaboration https://www.biopharmcatalyst.com/news/2026/alumis-alms-phase-3-data-cyclerion-cycn-collaboration"
X Link 2026-01-06T21:30Z 30.7K followers, [----] engagements

"🎙New episode of #Biotech Bulls and Breakthroughs is live Host John Gagliano sits down with @SheffStation to do a brief #JPM26 recap: 📈 [----] growth areas 🏢 Major M&A signals 💊 AI in biotech 🎧 https://biopharmcatalyst.com/podcast https://biopharmcatalyst.com/podcast"
X Link 2026-01-22T15:43Z 30.7K followers, [----] engagements

"$CALC discontinued its Phase [--] KOURAGE trial of Auxora in AKI with AHRF after an IDMC-recommended safety review flagged concerns warranting study design reevaluation despite no drug-related deaths or serious adverse events. The company will analyze unblinded data to guide potential future development in AKI while continuing plans for a pivotal trial in acute pancreatitis and advancing its second CRAC channel inhibitor. $CALC $ALT $RADX $PHGE $JUNS $STEX $FEED $KRRO $HIND $NUWE See More Pre-market Movers"
X Link 2026-01-28T13:40Z 30.7K followers, [----] engagements

"$AQST announced receipt of a CRL from the FDA for its sublingual film epinephrine treatment Anaphylm citing human factors deficiencies related to packaging and administration including difficulty opening the pouch and incorrect film placement. $AQST $THAR $SER $PHAR $MOLN $HIND $SXTC $VERO $APRE $NUWE See More Pre-market Movers https://www.biopharmcatalyst.com/news/2026/aquestive-therapeutics-aqst-crl-pharming-group-phar-crl https://www.biopharmcatalyst.com/news/2026/aquestive-therapeutics-aqst-crl-pharming-group-phar-crl"
X Link 2026-02-02T13:40Z 30.7K followers, [----] engagements

"$ELAB completed its third CNC shop acquisition buying SVM Machining for $2.25M plus earnouts expanding its precision manufacturing platform across aerospace medical and semiconductor sectors. $ELAB $EVO $ANL $CRBU $PHAR $APM $CDT $ATOS $HURA $VIVS See More Pre-market Movers https://www.biopharmcatalyst.com/news/2026/pmgc-holdings-elab-acquisition-evotec-evo-analyst-rating https://www.biopharmcatalyst.com/news/2026/pmgc-holdings-elab-acquisition-evotec-evo-analyst-rating"
X Link 2026-02-03T13:40Z 30.7K followers, [----] engagements

"$ERNA priced a $10.5M best-efforts public offering of 21M shares (or equivalents) and accompanying warrants at $0.50 per unit with warrants exercisable at $0.68 and expiring either five years post-issuance or [---] days after initial ERNA-101 Phase [--] cohort data release. Proceeds will fund development programs and operations with potential for $14.3M in additional gross proceeds if warrants are fully exercised. $ERNA $PLSE $ANEB $NVST $ATPC $ROIV $HURA $DNA $ESLA $ENVB See More Biotech Updates👇"
X Link 2026-02-06T21:46Z 30.7K followers, [----] engagements

"$EVMN reported Phase 2a results for EVO301 in moderate-to-severe atopic dermatitis meeting the primary efficacy endpoint with a 33% placebo-adjusted EASI improvement at week [--] and 23% of patients achieving IGA 0/1. The IL-18 inhibitor showed rapid statistically significant efficacy at weeks [--] [--] and [--] with a clean safety profile supporting advancement to a Phase 2b dose-ranging trial and broader development plans. $ABP $QNCX $PSNL $NKTR $PHIO $MIRA $PHG $HURA $TECX $ENSC See More Pre-market Movers"
X Link 2026-02-10T13:40Z 30.7K followers, [----] engagements

"$UPB reported Phase [--] VALIANT trial results for verekitug in severe asthma showing statistically significant reductions in exacerbation rates (up to 56%) and meaningful improvements in lung function and FeNO across key dosing regimens. $UPB $QNCX $STIM $ELAB $BFRI $MRNA $HURA $PHIO $AIM $DBVT See More Pre-market Movers https://www.biopharmcatalyst.com/news/2026/upstream-bio-upb-phase-2-data-quince-qncx-strategic-alternatives https://www.biopharmcatalyst.com/news/2026/upstream-bio-upb-phase-2-data-quince-qncx-strategic-alternatives"
X Link 2026-02-11T13:40Z 30.7K followers, [----] engagements

"$NVCR shares are up following FDA approval of Optune Pax for locally advanced pancreatic cancer marking the first new treatment in decades. The wearable device used with gemcitabine and nab-paclitaxel improved overall survival in a Phase [--] trial. $NVCR $QNCX $VKTX $MCRB $BRTX $BBIO $CTNM $PLRZ $ICLR $ABP See More Pre-market Movers https://www.biopharmcatalyst.com/news/2026/novocure-nvcr-approval-bridgebio-bbio-phase-3-dat https://www.biopharmcatalyst.com/news/2026/novocure-nvcr-approval-bridgebio-bbio-phase-3-dat"
X Link 2026-02-12T13:40Z 30.7K followers, [----] engagements

"$IMUX issued warrants to purchase up to [---------] shares (or pre-funded warrants) at $0.873/share potentially raising an additional $200 million. The warrants expire [--] days post-Phase [--] ENSURE top-line data announcement or February [--] [----]. This private placement expected to close around February [--] [----] supports Immunic's transition to the commercial stage. $IMUX $VTGN $CHRS $QNCX $BIO $OKYO $JSPR $BRTX $ABP $ARTL See More Pre-market Movers https://www.biopharmcatalyst.com/news/2026/immunic-imux-warrants-coherus-oncology-chrs-offering"
X Link 2026-02-13T13:40Z 30.7K followers, [----] engagements

"BioPharmCatalyst Weekly #Watchlist BioPharmCatalyst Weekly Watchlist: Key Phase [--] catalysts left for the quarter $OCUL $BCRX $GOSS $BCDA $KOD $TBPH $KPTI $PVLA https://www.biopharmcatalyst.com/news/2026/biopharmcatalyst-weekly-watchlist-key-phase-3-catalysts-left-for-the-quarter https://www.biopharmcatalyst.com/news/2026/biopharmcatalyst-weekly-watchlist-key-phase-3-catalysts-left-for-the-quarter"
X Link 2026-02-13T21:33Z 30.7K followers, [----] engagements

"BioPharmCatalyst updates: $BMRN PDUFA 1/27/17. $SPPI Adcom 9/14 + updates for $AVXL $RARE $VNDA $VRTX http://www.biopharmcatalyst.com/2016/07/bpc-july-27-updates-bmrn-pdufa-date-set-january-27-sppi-advisory-committee-meeting-september-14-updates-for-avxl-rare-vnda-vrtx/ http://www.biopharmcatalyst.com/2016/07/bpc-july-27-updates-bmrn-pdufa-date-set-january-27-sppi-advisory-committee-meeting-september-14-updates-for-avxl-rare-vnda-vrtx/"
X Link 2016-07-28T10:59Z 30.7K followers, [--] engagements

"On track for a record breaking traffic day at Thanks all for reading http://biopharmcatalyst.com http://biopharmcatalyst.com"
X Link 2017-08-30T01:27Z 30.7K followers, [--] engagements

"Biotech Updates 04/09: $AVXS +82% buyout $MNLO -77% $VTVT -65% fail $ACAD -23% safety concerns $ABBV MRK +ve data $AGIO $JNCE up on @ft_health $RDHL $CLSN $GTXI $NERV pipe updates https://www.biopharmcatalyst.com/news/2018/avexis-avxs-82-buyout-menlo-mnlo-77-and-vtvt-65-hit-by-trial-failures-acad-23-on-safety-concerns https://www.biopharmcatalyst.com/news/2018/avexis-avxs-82-buyout-menlo-mnlo-77-and-vtvt-65-hit-by-trial-failures-acad-23-on-safety-concerns"
X Link 2018-04-09T22:47Z 30.7K followers, [--] engagements

"BioPharmCatalyst Weekly #Watchlist January [--] 2023: Key Catalysts due for February and March [----] $TVTX $RETA $PHAR $EBS $CYTK $BPMC $APLS $INCY $CDTX $HALO $ACAD $RLYB $GILD $SNY $REGN $RDUS https://www.biopharmcatalyst.com/news/2023/key-catalysts-due-for-february-and-march-2023 https://www.biopharmcatalyst.com/news/2023/key-catalysts-due-for-february-and-march-2023"
X Link 2023-01-30T14:00Z 30.7K followers, 25.5K engagements

"BioPharmCatalyst Weekly #Watchlist February [--] 2023: Key Catalysts due for 2Q $CYCN $ASLN $ACHV $EVAX $HEPA $DBTX $HGEN $INO $NRXP $SLS $SRNE $TSHA $LXRX $VXRT https://www.biopharmcatalyst.com/news/2023/february-4-2023-key-catalysts-due-for-2q https://www.biopharmcatalyst.com/news/2023/february-4-2023-key-catalysts-due-for-2q"
X Link 2023-02-04T16:27Z 30.7K followers, [----] engagements

"BioPharmCatalyst Weekly #Watchlist February [--] 2023: Key phase [--] catalyst left for the 1Q $ATNM $IMGN $INO $EXEL $GNFT $ITCI $BCDA $SELB $CERE $PTCT $CYTH $RAIN $KRTX $PCRX $BCRX https://www.biopharmcatalyst.com/news/2023/february-11-2023-key-phase-3-catalyst-left-for-the-1q https://www.biopharmcatalyst.com/news/2023/february-11-2023-key-phase-3-catalyst-left-for-the-1q"
X Link 2023-02-13T15:18Z 30.7K followers, 37.4K engagements

"BioPharmCatalyst Weekly #Watchlist 02/18/23: Key phase 1/2 catalyst left for the 1Q $VKTX $FSTX $ASLN $ALT $ARMP $VTGN $TFFP $CYCN https://www.biopharmcatalyst.com/news/2023/february-18-2023-key-phase-1-2-catalyst-left-for-the-1q https://www.biopharmcatalyst.com/news/2023/february-18-2023-key-phase-1-2-catalyst-left-for-the-1q"
X Link 2023-02-20T14:00Z 30.7K followers, 13.3K engagements

"BioPharmCatalyst Weekly #Watchlist February [--] 2023: Key PDUFAs left for the 1Q $SNY $CYTK $AMGN $RETA $ACAD $CDTX $INCY $EBS $PHAR $REGN $BMRN $JAGX $PFE https://www.biopharmcatalyst.com/news/2023/february-25-2023-key-pdufa-s-catalyst-left-for-the-1q https://www.biopharmcatalyst.com/news/2023/february-25-2023-key-pdufa-s-catalyst-left-for-the-1q"
X Link 2023-02-27T13:28Z 30.7K followers, 14.2K engagements

"March [--] 2023: Key Upcoming Conference Catalysts to Watch $SRRK $ESPR $PDSB $CYTH $DICE $PBLA $AGEN $MLYS https://www.biopharmcatalyst.com/news/2023/march-4-2023-key-upcoming-conference-catalysts-to-watch https://www.biopharmcatalyst.com/news/2023/march-4-2023-key-upcoming-conference-catalysts-to-watch"
X Link 2023-03-04T16:00Z 30.7K followers, 25.8K engagements

"BioPharmCatalyst Weekly #Watchlist March [--] 2023: Key Catalysts left for 1Q [----] $BMEA $EBS $BOLT $MDNA $ANVS $MRKR $IOVA $VACC $JAGX $MREO $VKTX $VRTX $IMMX https://www.biopharmcatalyst.com/news/2023/march-25-2023-key-catalysts-left-for-1q-2023 https://www.biopharmcatalyst.com/news/2023/march-25-2023-key-catalysts-left-for-1q-2023"
X Link 2023-03-25T14:00Z 30.7K followers, 23.6K engagements

"BioPharmCatalyst Weekly #Watchlist Key Phase [--] Catalyst to Watch for the Next [--] Month $OMER $ARAV $PRFX $RVPH $CING $ACHV $LIAN $FBIO $DERM $PXMD $BTAI https://www.biopharmcatalyst.com/news/2023/april-1-2023-key-phase-3-catalyst-to-watch-for-the-next-6-months https://www.biopharmcatalyst.com/news/2023/april-1-2023-key-phase-3-catalyst-to-watch-for-the-next-6-months"
X Link 2023-04-03T13:43Z 30.7K followers, 10.1K engagements

"BioPharmCatalyst Weekly #Watchlist April [--] 2023: Key Regulatory Catalyst to Watch for the Next [--] Months $MCRB $ISEE $BLRX $VRCA $GMDA $OPNT $OTLK $ALDX $SWTX $GRTX $SRPT $OCUP $IBRX $AGEN $BIIB https://www.biopharmcatalyst.com/news/2023/april-15-2023-key-regulatory-catalyst-to-watch-for-the-next-6-months https://www.biopharmcatalyst.com/news/2023/april-15-2023-key-regulatory-catalyst-to-watch-for-the-next-6-months"
X Link 2023-04-15T16:00Z 30.7K followers, [----] engagements

"BioPharmCatalyst Weekly #Watchlist May [--] 2023: Key Catalysts Due Next [--] Months $SRPT $XFOR $ALDX $LIAN $HALO $COGT $PTCT $LXRX $VRNA $MESO $SAGE $BIIB $GRTX $DCTH $ISEE $RVNC $NBIX $IBRX $LIFE https://www.biopharmcatalyst.com/news/2023/may-6-2023-key-catalysts-due-next-6-months https://www.biopharmcatalyst.com/news/2023/may-6-2023-key-catalysts-due-next-6-months"
X Link 2023-05-06T14:00Z 30.7K followers, [----] engagements

"#ASCO23 is set to commence today and we are offering our subscriptions plans atup to 50% OFF Sign up or upgrade your accountduring the #ASCO2023 and lock in savings for up to a year For a list of companies presenting at ASCO refer to ourASCO23 Catalysts to Watch: or ourConference Calendar: https://www.biopharmcatalyst.com/calendars/conferences https://www.biopharmcatalyst.com/asco-23 https://www.biopharmcatalyst.com/sign-up https://www.biopharmcatalyst.com/calendars/conferences https://www.biopharmcatalyst.com/asco-23 https://www.biopharmcatalyst.com/sign-up"
X Link 2023-06-02T13:06Z 30.7K followers, [----] engagements

"BioPharmCatalyst Weekly #Watchlist June [--] 2023: Key Catalysts left for the Quarter (Post-Earnings Updated List) $ATNM $FGEN $TVTX $ALDX $PFE $CRVS $GNFT $VNDA $BTAI $FBIO $BCRX https://www.biopharmcatalyst.com/news/2023/june-3-2023-key-catalysts-left-for-the-quarter https://www.biopharmcatalyst.com/news/2023/june-3-2023-key-catalysts-left-for-the-quarter"
X Link 2023-06-05T13:00Z 30.7K followers, 21K engagements

"BioPharmCatalyst Weekly #Watchlist June [--] 2023: Key Catalysts Left Countdown to the End of the Quarter $CRVS $GNFT $VNDA $BTAI $ALDX $TSHA $ATAI $ALZN $FBIO $BMEA https://www.biopharmcatalyst.com/news/2023/june-10-2023-key-catalysts-left-countdown-to-the-end-of-the-quarter https://www.biopharmcatalyst.com/news/2023/june-10-2023-key-catalysts-left-countdown-to-the-end-of-the-quarter"
X Link 2023-06-10T15:48Z 30.7K followers, [----] engagements

"We are delighted to unveil our newest product BPC Portfolios A collection of portfolios with BPC's hand-selected tickers. Our flagship portfolio BPC [--] tracks [--] tickers measured by relative strength to the market and respective catalysts $xbi #biotech https://www.biopharmcatalyst.com/article/bpc-portfolio-index https://www.biopharmcatalyst.com/article/bpc-portfolio-index"
X Link 2023-06-13T19:52Z 30.7K followers, [----] engagements

"BioPharmCatalyst Weekly #Watchlist June [--] 2023: Key Catalysts left for the Quarter $CAPR $TVTX $AMRX $SRRK $AXSM $ARWR $VRNA $GNFT $ALDX $VTGN $TFFP $SONN $NGM $TSHA $PCSA $SRPT $LUMO $APLT $HALO $BMEA $EWTX $ALZN $IVA $ABUS $FBIO $ICPT https://www.biopharmcatalyst.com/news/2023/june-17-2023-key-catalysts-left-for-the-quarter https://www.biopharmcatalyst.com/news/2023/june-17-2023-key-catalysts-left-for-the-quarter"
X Link 2023-06-17T14:00Z 30.7K followers, 10.1K engagements

"BioPharmCatalyst Weekly #Watchlist June [--] 2023:Key Catalysts left for the Quarter: $CAPR $TVTX $AMRX $SRRK $AXSM $ARWR $VRNA $ARWR $VRNA $GNFT $ALDX $VTGN $TFFP $SONN $NGM $TSHA $PCSA $LUMO $APLT $HALO $BMEA $EWTX $ALZN $IVA $ABUS $FBIO $PHRRF $ICPT https://www.biopharmcatalyst.com/news/2023/june-17-2023-key-catalysts-left-for-the-quarter https://www.biopharmcatalyst.com/news/2023/june-17-2023-key-catalysts-left-for-the-quarter"
X Link 2023-06-24T14:00Z 30.7K followers, 15.8K engagements

"🎆 This Fourth of July ignite your biotech research Enjoy unlimited access to 1000+ catalysts model portfolios hedge fund holdings and other trading tools. 🎇Limited time offer so lock in your savings now🎇 $XBI $IBB $LLY $SGTX $BTAI $IMNM https://www.biopharmcatalyst.com/sign-up https://www.biopharmcatalyst.com/sign-up"
X Link 2023-06-29T13:44Z 30.7K followers, 1.2M engagements

"#PrimeDay is not just for $AMZN Save on our newest features including BPC portfolios hedge fund data and more Don't miss this opportunity to gain an edge in the #biotech market. 🚀💸 $XBI $IBB $LABU $CVKD $RXRX $LMNL $AVRO $SILK Start your FREE trial: https://biopharmcatalyst.com/sign-up https://biopharmcatalyst.com/sign-up"
X Link 2023-07-12T12:44Z 30.7K followers, [----] engagements

"BioPharmCatalyst Weekly #Watchlist July [--] 2023: Key PDUFA and regulatory catalysts for the next [--] months $ALDX $MESO $BCLI $IOVA $BLRX $MIRM $SWTX $GRTX $GSK $ANAB $TARS $OCUP $VALN $SPRY $CPRX $BMY https://www.biopharmcatalyst.com/news/2023/july-15-2023-key-pdufa-and-regulatory-catalysts-for-the-next-6-months https://www.biopharmcatalyst.com/news/2023/july-15-2023-key-pdufa-and-regulatory-catalysts-for-the-next-6-months"
X Link 2023-07-17T13:00Z 30.7K followers, 38.4K engagements

"August [--] 2023: Key Catalysts for the next [--] months $ALDX $CRMD $MRUS $AXSM $IMMP $PDSB $ADXS $GLTO $AMAM $IMGN $AGEN https://www.biopharmcatalyst.com/news/2023/august-5-2023-key-catalysts-for-the-next-6-months https://www.biopharmcatalyst.com/news/2023/august-5-2023-key-catalysts-for-the-next-6-months"
X Link 2023-08-05T03:31Z 30.7K followers, 13.6K engagements

"BioPharmCatalyst Weekly #Watchlist September [--] 2023: Key catalysts left for the quarter $OMER $BCLI $KOD $CRNX $INZY $CHRS $OCUP $FRTX $KRTX $SLNO $MREO $VXRT $ZVRA $CRDF $RLMD https://www.biopharmcatalyst.com/news/2023/september-9-2023-key-catalysts-left-for-the-quarter https://www.biopharmcatalyst.com/news/2023/september-9-2023-key-catalysts-left-for-the-quarter"
X Link 2023-09-11T13:17Z 30.7K followers, 11K engagements

"BioPharmCatalyst Weekly #Watchlist September [--] 2023: Key catalysts left for the quarter $SNDX $INZY $BLRX $GRCL $CHRS $OCUP $ARQT $ELTX $HOWL $CDTX $SPRY https://www.biopharmcatalyst.com/news/2023/september-16-2023-key-catalysts-left-for-the-quarter https://www.biopharmcatalyst.com/news/2023/september-16-2023-key-catalysts-left-for-the-quarter"
X Link 2023-09-18T13:00Z 30.7K followers, 216.8K engagements

"$SAVA announced a significant safety finding based on interim magnetic resonance imaging (MRI) brain data from Alzheimer's patients who are enrolled in a Phase [--] clinical trial of simufilam. The MRI data suggest simufilam is not associated with treatment-emergent amyloid-related imaging abnormalities or ARIA. $SAVA $BTAI $HOWL $SONN $AVXL $LIAN $CYBN $ATEC Read more👇 https://www.biopharmcatalyst.com/news/2023/cassava-sava-mri-data-bioxcel-phase-3-audit https://www.biopharmcatalyst.com/news/2023/cassava-sava-mri-data-bioxcel-phase-3-audit"
X Link 2023-10-25T20:45Z 30.7K followers, [----] engagements

"We are excited to announce an upcoming webinar Long-time biotech trader@SheffStation joins @BPharmCatalyst to discuss conducting due diligence how to best utilize #catalysts & what to be excited about in the current #biotech landscape Register Now: https://bit.ly/3P82b3S https://bit.ly/3P82b3S"
X Link 2024-03-06T15:50Z 30.7K followers, 44K engagements

"We are excited to offer our Elite Plus subscription at as low as $40/month* for the the upcoming #AACR2024 conference Our Elite & Elite Plus subscribers can access the AACR Dashboard here https://www.biopharmcatalyst.com/article/AACR-2024 https://www.biopharmcatalyst.com/article/AACR-2024"
X Link 2024-03-27T14:31Z 30.7K followers, 255.3K engagements

"Keep an eye on $CYTK - they are making waves in the treatment of diseases affecting muscle function. Aficamten is in late stage trials for Hypertrophic Cardiomyopathy #biotech #innovation #healthcare See their pipeline and upcoming 2Q catalysts here: https://www.biopharmcatalyst.com/company/CYTK https://www.biopharmcatalyst.com/company/CYTK"
X Link 2024-04-01T21:09Z 30.7K followers, [----] engagements

"BioPharmCatalyst Weekly #Watchlist Key Catalyst Remaining for 2Q Countdown to the End of the Quarter $GTHX $SVRA $NVCR $FGEN $PPBT $JAGX $PGEN $CADL $ANVS $SRPT $UNCY $SLN $THAR $BTAI https://www.biopharmcatalyst.com/news/2024/key-catalyst-remaining-for-2q-countdown-to-the-end-of-the-quarter https://www.biopharmcatalyst.com/news/2024/key-catalyst-remaining-for-2q-countdown-to-the-end-of-the-quarter"
X Link 2024-06-03T15:04Z 30.7K followers, [----] engagements

"$VRNA awaits FDA decision on June [--] for ensifentrine a groundbreaking COPD therapy. With $901.89M in cash theyre set for a strong future. Approval could make ensifentrine the first new inhaled #COPD treatment in 20+ years #biotech https://www.biopharmcatalyst.com/news/2024/key-catalyst-left-for-the-quarter-2 https://www.biopharmcatalyst.com/news/2024/key-catalyst-left-for-the-quarter-2"
X Link 2024-06-24T15:05Z 30.7K followers, 14.8K engagements

"Join webinar to explore the "hows" and "whys" of language models driving groundbreaking research advancements. We dive deep. You emerge an expert. Save your spot: https://bit.ly/4bmLZ7c http://Scientist.com https://bit.ly/4bmLZ7c http://Scientist.com"
X Link 2024-07-08T18:06Z 30.7K followers, [----] engagements

"$ADAP Ph [--] interim results for Lete-cel (IGNYTE-ESO) in sarcoma showed a 40% ORR consistent across indications with a median duration of response around [--] months. Full Ph [--] results expected late [----]. #Biotech https://www.biopharmcatalyst.com/news/2024/key-phase-1-2-catalyst-for-the-next-6-months https://www.biopharmcatalyst.com/news/2024/key-phase-1-2-catalyst-for-the-next-6-months"
X Link 2024-07-10T21:02Z 30.7K followers, [----] engagements

"$XCUR announced that it received formal notice that the Nasdaq Hearings Panel has determined to continue the Company's listing Read more👇 $RDHL $ALXO $LAB $OSTX $IMRX $EXAS $ALNY $TNDM $ARDX https://www.biopharmcatalyst.com/news/2024/redhill-rdhl-phase-3-data-alx-oncology-alxo-phase-2-data https://www.biopharmcatalyst.com/news/2024/redhill-rdhl-phase-3-data-alx-oncology-alxo-phase-2-data"
X Link 2024-08-01T20:56Z 30.7K followers, [----] engagements

"Upcoming catalyst for $PDSB: Full Phase [--] data from the VERSATILE-002 trial will be presented at #ESMO2024 on Sept 13-17. #Biotech #Oncology See more from $PDSB: https://www.biopharmcatalyst.com/company/PDSB https://www.biopharmcatalyst.com/company/PDSB"
X Link 2024-08-19T21:04Z 30.7K followers, 10.6K engagements

"ESMO [----] abstracts drop September 9th. 📅 Get ahead with our Conference Calendar and access a list of the company set to present headline drugs and indications Check it out: https://www.biopharmcatalyst.com/calendars/conferences https://www.biopharmcatalyst.com/calendars/conferences"
X Link 2024-09-02T15:02Z 30.7K followers, 14.3K engagements

"$OMIC announced it has received a non-binding acquisition proposal from Deerfield Management Company and affiliated funds to purchase all outstanding shares not owned by Deerfield for $10.00 per share in cash. Read more👇 $PRLD $TNON $INMB $OMIC $TIL $CNTA $IMRX $ALLR $RPTX https://twitter.com/i/web/status/1834694527233188168 https://www.biopharmcatalyst.com/news/2024/instil-bio-til-analyst-prelude-prld-phase-1-data https://twitter.com/i/web/status/1834694527233188168 https://www.biopharmcatalyst.com/news/2024/instil-bio-til-analyst-prelude-prld-phase-1-data"
X Link 2024-09-13T20:43Z 30.7K followers, [----] engagements

"BioPharmCatalyst Weekly #Watchlist Key Catalysts due for the Next [--] Months $KURA $CNTA $CELC $ARVN $LSTA $GYRE $AZTR $MLYS $NAMS $OCUP $VERU $PBM $IMRN https://www.biopharmcatalyst.com/news/2024/key-catalysts-due-by-april-2025 https://www.biopharmcatalyst.com/news/2024/key-catalysts-due-by-april-2025"
X Link 2024-11-02T14:44Z 30.7K followers, [----] engagements

"Black Friday is here 🎉 Save up to 50% on your biotech catalyst data subscription and supercharge your trading strategy. Don't miss our NEW Excel download featuredata at your fingertips just in time for Black Friday 💻📊 #BiotechInvesting #BlackFriday #StockMarket Start Your Free Trial: https://www.biopharmcatalyst.com/sign-up https://www.biopharmcatalyst.com/sign-up"
X Link 2024-11-21T15:06Z 30.7K followers, 17K engagements

"BioPharmCatalyst Weekly #Watchlist Key catalysts left for the quarter; Countdown to the end of the quarter $LXRX $GALT $FBIO $ARCT $PGEN $ABBV $AVIR $CGTX $OCS $PBYI $COCP $OSTX https://www.biopharmcatalyst.com/news/2024/key-catalysts-left-for-the-quarter-countdown-to-the-end-of-the-quarter https://www.biopharmcatalyst.com/news/2024/key-catalysts-left-for-the-quarter-countdown-to-the-end-of-the-quarter"
X Link 2024-12-14T16:51Z 30.7K followers, [----] engagements

"$QURE has received Breakthrough Therapy designation from the FDA for AMT-130 in the treatment of Huntingtons disease. This new designation adds to its existing RMAT Orphan Drug and Fast Track statuses further strengthening regulatory support for the gene therapy in a condition that currently lacks disease-modifying treatment options. See More Biotech Updates👇 $CHRO $CMND $QURE $LLY $APM $PTN $ALEC https://www.biopharmcatalyst.com/news/2025/channel-therapeutics-chro-merges-with-ligand-lgnd-subsidiaries-uniqure-qure-breakthrough-therapy-designation"
X Link 2025-04-17T20:11Z 30.7K followers, [----] engagements

"🚨 New Podcast Drop 🎙 The first episode of Biotech Bulls & Breakthroughs is live Brought to you by BioPharmCatalyst were diving into the latest moves in the biotech market with special guest Sheff from @SheffStation 🎧 Episode: "Tariffs GLP-1 Trends & Sheff's Catalyst To Watch" 👉 Listen now: https://www.biopharmcatalyst.com/podcast https://www.biopharmcatalyst.com/podcast"
X Link 2025-05-01T18:07Z 30.7K followers, 226.9K engagements

"$VERA reported its ORIGIN Phase [--] trial of atacicept in IgA nephropathy hit the primary endpoint cutting proteinuria [--] % versus placebo. See More Biotech Updates👇 $LYRA $VERA $BPMC $KYMR $XLO $TBPH $BNTX $VSTM $OGEN $TOVX https://www.biopharmcatalyst.com/news/2025/vera-vera-phase-3-data-lyra-lyra-phase-3-study https://www.biopharmcatalyst.com/news/2025/vera-vera-phase-3-data-lyra-lyra-phase-3-study"
X Link 2025-06-02T21:01Z 30.7K followers, [----] engagements

"$IPA discovered a highly conserved epitope across all four dengue virus serotypes using its HYFT-powered LENSai platform supporting the development of a potential universal dengue vaccine and validating its AI-native vaccine discovery engine. See More Biotech Updates👇 $HSDT $KRON $MAIA $OCGN $IPA $TPST $HOTH https://www.biopharmcatalyst.com/news/2025/helius-medical-hsdt-offering-immunoprecise-ipa-dengue-vaccine-program https://www.biopharmcatalyst.com/news/2025/helius-medical-hsdt-offering-immunoprecise-ipa-dengue-vaccine-program"
X Link 2025-06-05T20:21Z 30.7K followers, [----] engagements

"BioPharmCatalyst Weekly #Watchlist Key catalysts left for the quarter; Catalysts to Watch $AMGN $BCDA $IRD $NKTR $CELC $GSK $NUVL $UNCY $INMB $FBRX $INMB https://www.biopharmcatalyst.com/news/2025/key-catalysts-left-for-the-quarter-catalysts-to-watch https://www.biopharmcatalyst.com/news/2025/key-catalysts-left-for-the-quarter-catalysts-to-watch"
X Link 2025-06-14T13:39Z 30.7K followers, [----] engagements

"BioPharmCatalyst Weekly #Watchlist Key Phase [--] Catalysts for the Next [--] Months $ZYNE $PRAX $KPTI $AZN $DBVT $BTAI $AVBP $ABVX $XOMA $ENSC https://www.biopharmcatalyst.com/news/2025/key-phase-3-catalysts-for-the-next-6-months-5 https://www.biopharmcatalyst.com/news/2025/key-phase-3-catalysts-for-the-next-6-months-5"
X Link 2025-06-28T16:47Z 30.7K followers, [----] engagements

"🎧 New Episode Alert On Biotech Bulls and Breakthroughs John Gagliano and Sheff break down: 🔹 Key biotech market trends 🔹 Catalyst-driven trading strategies 🔹 Small-cap opportunities Tune in now 👉 #Biotech #StockMarket #TradingStrategies https://www.youtube.com/watchv=6aVtN0Oc1CI https://www.youtube.com/watchv=6aVtN0Oc1CI"
X Link 2025-07-10T18:07Z 30.7K followers, [----] engagements

"BioPharmCatalyst Weekly #Watchlist Key PDUFA and Regulatory Catalysts for the Next [--] Months $OMER $ABEO $RGNX $FBIO $CYTK $VNDA $OTLK $IONS $ARWR $TNXP $GRPH https://www.biopharmcatalyst.com/news/2025/key-pdufa-and-regulatory-catalysts-for-the-next-6-months-3 https://www.biopharmcatalyst.com/news/2025/key-pdufa-and-regulatory-catalysts-for-the-next-6-months-3"
X Link 2025-07-12T13:18Z 30.7K followers, [----] engagements

"BioPharmCatalyst Weekly #Watchlist Key Catalysts Due in Mid-2025 $REPL $OTLK $RARE $WINT $ATAI $CYBN $IXHL $TNXP $VYNE $ATHE $PFE $CRDF $PRAX https://www.biopharmcatalyst.com/news/2025/key-catalysts-due-in-mid-2025 https://www.biopharmcatalyst.com/news/2025/key-catalysts-due-in-mid-2025"
X Link 2025-07-19T15:00Z 30.7K followers, [----] engagements

"$CARM will receive a $5M private placement investment from $OCGN as part of its merger with Ocugen subsidiary OrthoCellix with terms ensuring Ocugen receives equal or better investor rights; the deal is contingent on shareholder and regulatory approvals"
X Link 2025-08-29T21:29Z 30.7K followers, [----] engagements

"OrbiMed Advisors LLC and other beneficial owners reported acquiring common shares of $STTK sending the shares higher today. $ See More Biotech Updates👇 https://www.biopharmcatalyst.com/news/2025/shattuck-labs-sttk-shares-acquired-alphaton-prtg-financing-for-ton-tokens https://www.biopharmcatalyst.com/news/2025/shattuck-labs-sttk-shares-acquired-alphaton-prtg-financing-for-ton-tokens"
X Link 2025-09-03T20:30Z 30.7K followers, [----] engagements

"$ANEB updated on its going-private process noting it has received interest from potential partners and will review all strategic alternativesincluding a reverse stock split asset sale or mergerwhile still planning a shareholder vote on the split though no timeline or outcome is assured. $HCWB $ANEB $SGMO $MODD $SMMT $MIRA $ADXN $THAR $SKYE $TNON $COCP See More Pre-market Movers https://www.biopharmcatalyst.com/news/2025/anebulo-pharmaceuticals-aneb-going-private-update-sangamo-sgmo-cfo-resigns"
X Link 2025-09-12T12:40Z 30.7K followers, [----] engagements

"$APYX priced a public offering of 2.76M shares at $3.62 expecting to raise gross proceeds of https://www.biopharmcatalyst.com/news/2025/can-fite-canf-liver-cancer-data-apollomics-aplm-board-leadership https://www.biopharmcatalyst.com/news/2025/can-fite-canf-liver-cancer-data-apollomics-aplm-board-leadership"
X Link 2025-11-18T21:30Z 30.7K followers, [----] engagements

"Merry Xmas Pleased to let readers know that BPC will resume all services Jan [--]. Databases to be updated over Xmas. http://www.biopharmcatalyst.com/2015/12/biopharmcatalyst-to-resume-all-services-january-4/ http://www.biopharmcatalyst.com/2015/12/biopharmcatalyst-to-resume-all-services-january-4/"
X Link 2015-12-24T14:00Z 30.7K followers, [--] engagements

"Happy NY all Still on track to have the FDA Calendar and Company Pipeline databases updated by Monday http://www.biopharmcatalyst.com/fda-calendar/ http://www.biopharmcatalyst.com/fda-calendar/"
X Link 2016-01-01T13:45Z 30.7K followers, [--] engagements

"Pleased to announce FDA Calendar + Pipeline database have been updated. [----] IPOs added soon http://www.biopharmcatalyst.com/clinical-database/ http://www.biopharmcatalyst.com/fda-calendar/ http://www.biopharmcatalyst.com/clinical-database/ http://www.biopharmcatalyst.com/fda-calendar/"
X Link 2016-01-04T12:30Z 30.7K followers, [--] engagements

"Feels great to get the new off the ground. See what's in store here https://www.youtube.com/watchv=v-FRWLIiaSI http://BioPharmCatalyst.com https://www.youtube.com/watchv=v-FRWLIiaSI http://BioPharmCatalyst.com"
X Link 2016-08-24T11:20Z 30.7K followers, [--] engagements

"10 Biotech Stocks to put on your Watchlist: $DPRX $DRRX $GNCA $KITE $MSTX $OPHT $OPXA $PTIE $PTN $VRTX http://biopharmcatalyst.com/news/2016/biotech-stock-watchlist-for-week-commencing-september-19 http://biopharmcatalyst.com/news/2016/biotech-stock-watchlist-for-week-commencing-september-19"
X Link 2016-09-17T13:00Z 30.7K followers, [--] engagements

"Upcoming 4Q catalysts. 40+ binary events left for 4Q Selection here $AKAO $ARDM $BLUE $CERC $FOLD $MDGN $OPHT $SGYP http://biopharmcatalyst.com/news/2016/biotech-stock-watch-list-upcoming-catalysts-as-of-november-21-1016 http://biopharmcatalyst.com/news/2016/biotech-stock-watch-list-upcoming-catalysts-as-of-november-21-1016"
X Link 2016-11-19T20:01Z 30.7K followers, [--] engagements

"Biotech Stock Watch List 11/28 + list of [--] recent Reverse Split stocks to keep on your low float radar. http://biopharmcatalyst.com/news/2016/keeping-track-of-low-float-biotech-stocks-biotech-stock-watch-list-of-week-commencing-november-28-2016 http://biopharmcatalyst.com/news/2016/keeping-track-of-low-float-biotech-stocks-biotech-stock-watch-list-of-week-commencing-november-28-2016"
X Link 2016-11-26T19:24Z 30.7K followers, [--] engagements

"Biotech Stock Watch List - Wk of 12/19: $ACAD Ph2 $ANTH $ITEK $LXRX $OTIC Ph3 $CEMP PDUFA $PTLA NDA acceptance http://biopharmcatalyst.com/news/2016/biotech-stock-watch-list-for-week-commencing-december-19-2016 http://biopharmcatalyst.com/news/2016/biotech-stock-watch-list-for-week-commencing-december-19-2016"
X Link 2016-12-17T15:33Z 30.7K followers, [--] engagements

"First [----] BPC Biotech Stock Watch List: Upcoming Jan events: $AGRX Ph3 $ITEK Ph3 $TENX Ph3 $PLX Ph2 (interim) http://biopharmcatalyst.com/news/2016/happy-new-year-first-biotech-stock-watch-list-for-2017 http://biopharmcatalyst.com/news/2016/happy-new-year-first-biotech-stock-watch-list-for-2017"
X Link 2016-12-31T14:30Z 30.7K followers, [--] engagements

"BPC Week in Review + Jan Event Watch List $DMTX HemB $FGEN Panc+Ph3 China Jan/Feb $NBIX Ph2 $SGYP PDUFA $TENX Ph3 http://biopharmcatalyst.com/news/2017/biopharmcatalyst-expands-coverage-biotech-week-in-review-six-upcoming-january-catalysts http://biopharmcatalyst.com/news/2017/biopharmcatalyst-expands-coverage-biotech-week-in-review-six-upcoming-january-catalysts"
X Link 2017-01-14T14:30Z 30.7K followers, [--] engagements

"BioPharmCatalyst NEW tool: Track #Biotech intra-day: - Highest gainers - Greatest losers - Unusual Volume https://www.biopharmcatalyst.com/biotech-stocks https://www.biopharmcatalyst.com/biotech-stocks"
X Link 2017-07-08T13:00Z 30.7K followers, [--] engagements

"16 PDUFA/Adcom dates Aug/Sep+Wk in Review PDUFA $VRX $ADMS $AMGN $AZN $KMDA $MRK $NEOS $NVS Adcom: $GSK $PTCT +more https://www.biopharmcatalyst.com/news/2017/16-upcoming-pdufa-dates-and-advisory-committee-meetings-for-august-september-week-in-review-august-4-2017 https://www.biopharmcatalyst.com/news/2017/16-upcoming-pdufa-dates-and-advisory-committee-meetings-for-august-september-week-in-review-august-4-2017"
X Link 2017-08-05T12:59Z 30.7K followers, [--] engagements

"15 of 50+ Biotech 3Q catalysts: $SAGE $ALNY $AVEO $AXON $FOLD $INSM $NBRV $NEOS $NVS $OTIC $PRQR $PTCT $VSAR $VSTM https://www.biopharmcatalyst.com/news/2017/15-key-biotech-stock-catalysts-for-3q-2017-biotech-week-in-review-august-25-2017 https://www.biopharmcatalyst.com/news/2017/15-key-biotech-stock-catalysts-for-3q-2017-biotech-week-in-review-august-25-2017"
X Link 2017-08-25T20:07Z 30.7K followers, [--] engagements

"Biotech Review+ [--] catalysts left for Sept $ABUS/ $ALNY $AXON $BCRX $FCSC $FOLD $NBRV $PRQR $PTCT $RDHL $VSAR $ZGNX https://www.biopharmcatalyst.com/news/2017/12-biotech-catalysts-to-round-out-september-biotech-week-in-review-september-15-2017 https://www.biopharmcatalyst.com/news/2017/12-biotech-catalysts-to-round-out-september-biotech-week-in-review-september-15-2017"
X Link 2017-09-15T20:24Z 30.7K followers, [--] engagements

"Biotech Wk in Review 9/29+ upcoming biotech events- early Oct: $ACRX $AERI $CAPR $FENC $FOLD $FLXN $ONCE $RDHL $SRPT https://www.biopharmcatalyst.com/news/2017/10-biotech-events-for-the-first-two-weeks-of-october-2017-week-in-review-09-29-2017 https://www.biopharmcatalyst.com/news/2017/10-biotech-events-for-the-first-two-weeks-of-october-2017-week-in-review-09-29-2017"
X Link 2017-09-30T23:36Z 30.7K followers, [--] engagements

"Upcoming October biotech catalysts $ACRX $AERI $ALXN $ATRS $DBVT $FENC $LOXO $MYL $ONCE $PTCT +Biotech Wk in Review https://www.biopharmcatalyst.com/news/2017/8-key-biotech-catalysts-on-the-table-for-october-biotech-week-in-review-october-6-2017 https://www.biopharmcatalyst.com/news/2017/8-key-biotech-catalysts-on-the-table-for-october-biotech-week-in-review-october-6-2017"
X Link 2017-10-07T16:11Z 30.7K followers, [--] engagements

"4Q Biotech Catalysts $ABBV $ALXN $AXON $BLUE $CALA $CEMP $CRIS $CYTK $DBVT $EARS $FPRX $LOXO $PTI $RVNC +Wk in Rev https://www.biopharmcatalyst.com/news/2017/15-biotech-stock-catalysts-for-4q-2017-week-in-review-october-13-2017 https://www.biopharmcatalyst.com/news/2017/15-biotech-stock-catalysts-for-4q-2017-week-in-review-october-13-2017"
X Link 2017-10-14T12:45Z 30.7K followers, [--] engagements

"Biotech updates a little late today.spent the day hiking. If you're up north and looking for some summer sun with a decent view then you should come on down and check us out #NewZealand #IshmusPeak #Wanaka #LakeHawea"
X Link 2017-12-22T03:49Z 30.7K followers, [--] engagements

"Upcoming 1Q [----] PDUFA and Advisory Committee dates; Biotech Wk in Review 12/22: $ARDM $APRI $GILD $LLY $LPCN $KMPH $OTIC $PCRX $SGYP $VRTX https://www.biopharmcatalyst.com/news/2017/pdufa-and-advisory-committee-meeting-dates-for-1q-2018-biotech-stock-week-in-review https://www.biopharmcatalyst.com/news/2017/pdufa-and-advisory-committee-meeting-dates-for-1q-2018-biotech-stock-week-in-review"
X Link 2017-12-24T20:11Z 30.7K followers, [--] engagements

"10 Biotech Catalysts slated for January 2018: $KALA $RVNC $SAGE $VNDA $EIGR $AXSM $AXON $BOLD $LPCN $ARDM https://www.biopharmcatalyst.com/news/2017/10-biotech-catalysts-scheduled-for-january-2018 https://www.biopharmcatalyst.com/news/2017/10-biotech-catalysts-scheduled-for-january-2018"
X Link 2017-12-30T14:05Z 30.7K followers, [--] engagements

"Biotech Stock Catalysts early [----] (Jan/Feb focus): Jan $BLRX $TCON (ASCO GI abstracts out 1/16) $EIGR $SGYP $KDMN $PHMMF Feb $AIMT $EARS "Early 18" $MDGL $MRNS 1Q18 $BHVN $DERM https://www.biopharmcatalyst.com/news/2018/upcoming-early-2018-biotech-catalysts-biotech-week-in-review https://www.biopharmcatalyst.com/news/2018/upcoming-early-2018-biotech-catalysts-biotech-week-in-review"
X Link 2018-01-14T14:00Z 30.7K followers, [--] engagements

"20 Micro/Small Cap Biotech Catalysts left for 1Q [----]. Will cover mid/large cap nxt wk: $AIMT $APRI $ARNA $BHVN $CDTX $DERM $ESPR $IMGN $KDMN $KMPH $KURA $MDGL $MRNS $MYOK $PCRX $SMMT $SRNE $TTPH $VYGR $ABIO https://www.biopharmcatalyst.com/news/2018/20-micro-and-small-cap-biotech-stock-catalysts-left-for-1q-2018-biotech-week-in-review https://www.biopharmcatalyst.com/news/2018/20-micro-and-small-cap-biotech-stock-catalysts-left-for-1q-2018-biotech-week-in-review"
X Link 2018-01-20T17:13Z 30.7K followers, [--] engagements

"Biotech Events left slated for Feb + Week in Review: $AMAG / $ATRS $AIMT $APRI $KDMN $KMPH $KURA $MRNS $NVAX $PCRX $SRNE $VRTX https://www.biopharmcatalyst.com/news/2018/11-upcoming-biotech-stock-events-slated-for-february-biotech-week-in-review https://www.biopharmcatalyst.com/news/2018/11-upcoming-biotech-stock-events-slated-for-february-biotech-week-in-review"
X Link 2018-02-10T22:40Z 30.7K followers, [--] engagements

"Upcoming key Phase [--] Biotech Catalysts left for 1Q + wk in Review: $AIMT $ANTH $BHVN $CLSD $DERM $ESPR $GWPH $IMGN $NBIX $NRBV (spring) $REGN $VBLT $VTVT https://www.biopharmcatalyst.com/news/2018/phase-3-biotech-catalysts-to-watch-1q-2018-biotech-week-in-review https://www.biopharmcatalyst.com/news/2018/phase-3-biotech-catalysts-to-watch-1q-2018-biotech-week-in-review"
X Link 2018-02-17T12:12Z 30.7K followers, [--] engagements

"17 Key Biotech Stock Catalysts to watch in March + Biotech Wk in Review: $ANAB $ANTH $ARNA $BHVN $CDTX $CLSD $DERM $ESPR $GTHX $IMGN $MRNS $MYOK $REGN $TSRO $VBLT $VNDA $VYGR https://www.biopharmcatalyst.com/news/2018/17-key-biotech-stock-catalysts-to-watch-in-march-biotech-week-in-review https://www.biopharmcatalyst.com/news/2018/17-key-biotech-stock-catalysts-to-watch-in-march-biotech-week-in-review"
X Link 2018-03-03T13:50Z 30.7K followers, [--] engagements

"Biotech Stocks to watch at #aacr18 (April 14-16); Biotech Week in Review: $DVAX $BMY $MRK $ARQL $CLDX $TSRO $ONCS $TOCA $BPMC https://www.biopharmcatalyst.com/news/2018/biotech-stocks-to-watch-at-aacr-biotech-week-in-review https://www.biopharmcatalyst.com/news/2018/biotech-stocks-to-watch-at-aacr-biotech-week-in-review"
X Link 2018-03-31T17:20Z 30.7K followers, [--] engagements

"Biotech updates 4/11: $BLCM clinical hold lifted +17% $ALXN to acquire Wilson Therapeutics $NVAX offering $CBAY +11% PBC data $ICPT -7% $SMMT data 3Q + $RETA $BVXV $NKTR pipeline updates https://www.biopharmcatalyst.com/news/2018/bellicum-blcm-clinical-hold-lifted-alexion-alxn-to-acquire-wilson-therapeutics-for-855m https://www.biopharmcatalyst.com/news/2018/bellicum-blcm-clinical-hold-lifted-alexion-alxn-to-acquire-wilson-therapeutics-for-855m"
X Link 2018-04-11T22:04Z 30.7K followers, [--] engagements

"10 upcoming Small-Cap Phase [--] catalysts slated for 2Q; Biotech Week in Review $ZGNX $TGTX $CARA $ZEAL $AVEO $IMGN $ESPR $ATXI $CTIC $PFNX https://www.biopharmcatalyst.com/news/2018/10-phase-3-small-cap-biotech-stock-catalysts-slated-for-2q-biotech-week-in-review https://www.biopharmcatalyst.com/news/2018/10-phase-3-small-cap-biotech-stock-catalysts-slated-for-2q-biotech-week-in-review"
X Link 2018-04-22T13:20Z 30.7K followers, [--] engagements

"15 PDUFA/Advisory Committee dates slated for May/June: $AKAO $AMGN $ARRY $BMRN $DERM $DOVA $DRRX $GWPH $INCY $INSY $KTOV $LLY $PTIE $REPH $SCPH $TXMD $VRX https://www.biopharmcatalyst.com/news/2018/15-advisory-committee-and-pdufa-dates-slated-for-may-and-june-biotech-week-in-review https://www.biopharmcatalyst.com/news/2018/15-advisory-committee-and-pdufa-dates-slated-for-may-and-june-biotech-week-in-review"
X Link 2018-05-13T13:30Z 30.7K followers, [--] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing